Prolactin has a pathogenic role in systemic lupus erythematosus

Area of Science:

• Immunology
• Endocrinology
• Rheumatology

Background:

• Prolactin (PRL) is a peptide hormone produced by the pituitary and immune cells.
• PRL modulates immune responses through receptor binding and JAK-STAT signaling.
• Hyperprolactinemia is observed in systemic lupus erythematosus (SLE) patients, correlating with disease activity.

Purpose of the Study:

• To investigate the role of prolactin in SLE pathogenesis.
• To evaluate the therapeutic potential of PRL suppression in SLE.

Main Methods:

• Review of existing literature on PRL, immune function, and SLE.
• Analysis of correlations between serum PRL levels and SLE manifestations.
• Examination of experimental data from murine lupus models treated with bromocriptine.
• Assessment of clinical trial results for bromocriptine in human SLE.

Main Results:

• Hyperprolactinemia is linked to increased SLE disease activity, IgG, anti-DNA antibodies, and immune complex formation.
• PRL contributes to lupus nephritis, neuropsychiatric, and cutaneous manifestations.
• Bromocriptine treatment in mice reduced lupus activity, extended lifespan, and restored immune function.
• Clinical trials indicate bromocriptine offers therapeutic benefits for human SLE, including during pregnancy.

Conclusions:

• Prolactin significantly contributes to the pathogenesis and clinical presentation of SLE.
• Suppression of prolactin secretion may be a viable therapeutic strategy for managing SLE.